Aeglea Biotherapeutics, Inc.
|Number of Estimates|
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
Market Cap: 136 Million
Primary Exchange: NASDAQ
Shares Outstanding: 29.1 Million
Float: 25.2 Million
Sector: Health Technology
Industry: Pharmaceuticals: Major
Longest drawdown: 1531 trading days
From: 2016-04-08 To: 2020-03-30
|Ex-Date||Payment Date||Record Date||Declared Date||Amount||Flag||Dividend Type||Qualified||Indicated|
|Ex-Date||Declared Date||Record Date||Payment Date||Ratio||To Factor||For Factor|